Berlin, Germany

Florian Kern

This inventor holds 4 USPTO granted patents and 2 EPO patents. Top assignee: Other. Active years: 2006-2015.


% Patents Active = 50.0


Average Co-Inventor Count = 5.7

ph-index = 2

Forward Citations = 19(Granted Patents)


Company Filing History:

goldMedal4 out of 834,307 
Other
 patents

Years Active: 2006-2015

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Florian Kern: Innovator in Immunology

Introduction

Florian Kern is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of immunology, holding a total of 4 patents. His work focuses on methods and peptides that enhance the understanding and treatment of immune responses.

Latest Patents

Kern's latest patents include a method for identifying T-cell stimulating protein fragments. This invention outlines a systematic approach to detect and synthesize protein fragments that can stimulate T-cells, ultimately aiding in the development of immunostimulatory medications. Another significant patent involves peptides for vaccination against human cytomegalovirus (CMV). This invention provides valuable tools for determining exposure to CMV and measuring immune responses in subjects.

Career Highlights

Throughout his career, Florian Kern has worked with various organizations, contributing to advancements in immunology. His innovative approaches have positioned him as a key figure in the development of therapeutic strategies targeting immune responses.

Collaborations

Kern has collaborated with esteemed colleagues such as Hans-Dieter Volk and Petra Reinke. These partnerships have further enriched his research and development efforts in the field.

Conclusion

Florian Kern's contributions to immunology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in immunotherapy and vaccine development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…